Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Epeius Biotechnologies has announced that the interim analysis of an on-going Phase I/II study confirmed Rexin-G's anti-tumor activity with no major toxicity in patients with metastatic chemotherapy-resistant pancreatic cancer.
Subscribe to our email newsletter
The clinical trial design included five escalating doses of intravenous Rexin-G ranging from 1 x 10e11 cfu twice a week to 4 x 10e11 cfu three times a week for four weeks. Interim analysis showed no dose limiting toxicities in nine evaluable patients who received dose levels 1-3. Furthermore, the analysis showed decrease in tumor size or disease stabilization (by Recist), decreased metabolic activity in tumors (by PET-CT scan), reduction in tumor marker levels, and clinical benefit in patients receiving dose level 3.
The second Phase of the Rexin-G study has now opened wherein six patients will receive dose levels four and five, respectively, as the Phase I/II adaptive study design continues to evaluate the over-all safety of Rexin-G and to determine the optimal dosing regimen for Rexin-G that would document the clinical benefits required to support a Phase II/III pivotal trial.
Sant Chawla, principal investigator of the Phase I/II study, said: “I am happy with the positive results of Rexin-G seen in pancreatic cancer, and look forward to obtaining even better results with progressively higher doses of Rexin-G.”